Fennec Pharmaceuticals FENC Stock
Fennec Pharmaceuticals Price Chart
Fennec Pharmaceuticals FENC Financial and Trading Overview
| Fennec Pharmaceuticals stock price | 11.29 USD |
| Previous Close | 11.35 USD |
| Open | 11.47 USD |
| Bid | 8.11 USD x 200 |
| Ask | 14.52 USD x 200 |
| Day's Range | 11.22 - 11.65 USD |
| 52 Week Range | 5.65 - 13.25 USD |
| Volume | 189.4K USD |
| Avg. Volume | 237.19K USD |
| Market Cap | 395.91M USD |
| Beta (5Y Monthly) | 1.066 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.12 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.67 USD |
FENC Valuation Measures
| Enterprise Value | 354.66M USD |
| Trailing P/E | N/A |
| Forward P/E | 11.859243 |
| PEG Ratio (5 yr expected) | 1.47 |
| Price/Sales (ttm) | 6.6852674 |
| Price/Book (mrq) | 9.322874 |
| Enterprise Value/Revenue | 5.989 |
| Enterprise Value/EBITDA | -347.251 |
Trading Information
Fennec Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.066 |
| 52-Week Change | 30.52% |
| S&P500 52-Week Change | 18.67% |
| 52 Week High | 13.25 USD |
| 52 Week Low | 5.65 USD |
| 50-Day Moving Average | 10.49 USD |
| 200-Day Moving Average | 8.43 USD |
FENC Share Statistics
| Avg. Volume (3 month) | 237.19K USD |
| Avg. Daily Volume (10-Days) | 263.1K USD |
| Shares Outstanding | 35.07M |
| Float | 19.78M |
| Short Ratio | 4.07 |
| % Held by Insiders | 14.31% |
| % Held by Institutions | 54.31% |
| Shares Short | 615.87K |
| Short % of Float | 2.02% |
| Short % of Shares Outstanding | 1.76% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -5.48% |
| Operating Margin (ttm) | 9.71% |
| Gross Margin | 93.72% |
| EBITDA Margin | -1.72% |
Management Effectiveness
| Return on Assets (ttm) | -1.16% |
| Return on Equity (ttm) | -18.58% |
Income Statement
| Revenue (ttm) | 59.22M USD |
| Revenue Per Share (ttm) | 1.85 USD |
| Quarterly Revenue Growth (yoy) | 85.20% |
| Gross Profit (ttm) | 55.51M USD |
| EBITDA | -1021333 USD |
| Net Income Avi to Common (ttm) | -3250000 USD |
| Diluted EPS (ttm) | -0.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 41.25M USD |
| Total Cash Per Share (mrq) | 1.18 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.85 |
| Book Value Per Share (mrq) | 1.211 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2040000 USD |
| Levered Free Cash Flow (ttm) | 1.07M USD |
Profile of Fennec Pharmaceuticals
| Country | United States |
| State | NC |
| City | Research Triangle Park |
| Address | 68 TW Alexander Drive |
| ZIP | 27709 |
| Phone | 919 636 4530 |
| Website | https://www.fennecpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 35 |
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Q&A For Fennec Pharmaceuticals Stock
What is a current FENC stock price?
Fennec Pharmaceuticals FENC stock price today per share is 11.29 USD.
How to purchase Fennec Pharmaceuticals stock?
You can buy FENC shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Fennec Pharmaceuticals?
The stock symbol or ticker of Fennec Pharmaceuticals is FENC.
Which industry does the Fennec Pharmaceuticals company belong to?
The Fennec Pharmaceuticals industry is Biotechnology.
How many shares does Fennec Pharmaceuticals have in circulation?
The max supply of Fennec Pharmaceuticals shares is 35.07M.
What is Fennec Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Fennec Pharmaceuticals PE Ratio is now.
What was Fennec Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Fennec Pharmaceuticals EPS is -0.12 USD over the trailing 12 months.
Which sector does the Fennec Pharmaceuticals company belong to?
The Fennec Pharmaceuticals sector is Healthcare.
Fennec Pharmaceuticals FENC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26180.46 USD — |
+0.43
|
6.32B USD — | 26049.3 USD — | 26269.85 USD — | — - | 6.32B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
144.19 USD — |
+1.72
|
— — | 142.98 USD — | 144.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1367.82 USD — |
+1.36
|
— — | 1351.7 USD — | 1374.29 USD — | — - | — — |
- {{ link.label }} {{link}}
